Trial Profile
Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS 15-2139)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Lenvatinib (Primary)
- Indications Advanced breast cancer; Non-small cell lung cancer; Sarcoma; Solid tumours
- Focus Therapeutic Use
- 01 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Nov 2021.
- 22 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 04 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 Dec 2020.